Activities of human papillomavirus 16 E6 natural variants in human keratinocytes

Journal of Medical Virology

Volumn 79, Issue 11, 2007, Pages 1751-1760

  Asadurian, Yulia ^a   Kurilin, Helena ^a   Lichtig, Hava ^a   Jackman, Anna ^a   Gonen, Pinhas ^a   Tommasino, Massimo ^b   Zehbe, Ingeborg ^c   Sherman, Levana ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c THUNDER BAY REGIONAL HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Bax; E6 protein functions; HPV polymorphism; HPV16 natural variants; Human keratinocytes; p53

Indexed keywords

CALCIUM; PROTEIN BAX; PROTEIN E6; PROTEIN P53;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CANCER RISK; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; KERATINOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VIRUS ONCOGENE; VIRUS VIRULENCE; WART VIRUS; WESTERN BLOTTING;

ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TRANSFORMED; CELLS, CULTURED; DOWN-REGULATION; HUMAN PAPILLOMAVIRUS 16; HUMANS; KERATINOCYTES; MICE; NIH 3T3 CELLS; ONCOGENE PROTEINS, VIRAL; POLYMORPHISM, GENETIC; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; VARIATION (GENETICS);

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 34748839201     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20978     Document Type: Article

References (53)

1. Alfandari J, Shnitman Magal S, Jackman A, Schlegel R, Gonen P, Sherman L. 1999. HPV16 E6 oncoprotein inhibits apoptosis induced during serum-calcium differentiation of foreskin human keratinocytes. Virology 257:383-396.
2. Allen-Hoffmann BL, Schlasser SJ, Ivarie CA, Sattler CA, Meissner LF, O'Connor SL. 2000. Normal growth and differentiation in a spontaneously immortalized near-diploid keratinocyte cell line, NIKs. J Invest Dermatol 114:444-455.
3. Baseman JG, Koutsky LA. 2005. The epidemiology of human papillomavirus infections. J Clin Virol 32:16-24.
4. Bernard H-U, Calleja-Macias IE, Dunn ST. 2006. Genome variation of human papillomavirus types: Phylogenetic and medical implications. Int J Cancer 118:1071-1076.
5. Berumen J, Ordonez RM, Lazcano E, Salmeron J, Galvan SC, Estrada RA, Yunes E, Garcia-Carranca A, Gonzalez-Lira G, Madrigal-de-la Campa A. 2001. Asian-American variants of human papillomavirus 16 and risk for cervical cancer: A case-control study. J Natl Cancer Inst 93:1325-1330.
6. Bontkes HJ, van Duin M, de Gruijl TD, Duggan-Keen MF, Walboomers JM, Stukart MJ, Verheijen RH, Heimerhorst TJ, Meijer CJ, Scheper RJ, Stevens FR, Dyer PA, Sinnott P, Stern PL. 1998. HPV 16 infection and progression of cervical intraepithelial neoplasia: Analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer 78:166-171.
7. Brady CS, Duggan-Keen MF, Davidson JA, Varley JM, Stern PL. 1999. Human papillomavirus type 16 variants in cervical carcinoma: Relationship to host genetic factors and clinical parameters. J Gen Virol 80:3233-3240.
8. Burd EM. 2003. Human papillomavirus and cervical cancer. Clin Microbiol Rev 16:1-17.
9. Chakrabarti O, Krishna S. 2003. Molecular interactions of "high risk" human papillomaviruses E6 and E7 oncoproteins: Implications for tumour progression. J Biosci 28:337-348.
10. Chakrabarti O, Veeraraghavalu K, Tergaonkar V, Liu Y, Androphy EJ, Stanley MA, Krishna S. 2004. Human papillomavirus type 16 E6 amino acid 83 variants enhance E6-mediated MAPK signaling and differentially regulate tumorigenesis by Notch signaling and oncogenic Ras. J Virol 78:5934-5945.
11. Conrad Stoppler M, Ching K, Stoppler LH, Clancy K, Schlegel R, Icenogle J. 1996. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol 70:6987-6993.
12. Cooper B, Schneider S, Bohl J, Jiang YH, Beaudet A, Vande Pol S. 2003. Requirement of E6AP and the features of human papillomavirus E6 necessary to support degradation of p53. Virology 306:87-99.
13. Ellis JRM, Keating PJ, Baird J, Hounsell EF, Renouf DV, Rowe M, Hopkins D, Duggan-Keen MF, Bartholomew JS, Young LS, Stern PL. 1995. The association of an HPV 16 onocogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat Med 1:464-470.
14. Ferenczy A, Franco E. 2002. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 3:11-16.
15. Flores ER, Lambert PF. 1997. Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle. J Virol 71:7167-7179.
16. Flores ER, Allen-Hoffman BL, Lee D, Lambert PF. 2000. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J Virol 74:6622-6631.
17. Foster SA, Demers GW, Etscheid CG, Galloway DA. 1994. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol 68:5698-5705.
18. Giannoudis A, Herrington CS. 2001. Human papillomavirus variants and squamous neoplasia of the cervix. J Pathol 193:295-302.
19. Grodzki M, Besson G, Clavel C, Arslan A, Franceschi S, Birembaut P, Tommasino M, Zehbe I. 2006. Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant. Cancer Epidemiol Biomarkers Prev 15:820-822.
20. Hildesheim A, Wang SS. 2002. Host and viral genetics and risk of cervical cancer: A review. Virus Res 89:229-240.
21. Ho L, Chan SY, Burk RD, Das BC, Fujinaga K, Icenogle JP, Kahn T, Kiviat N, Lancaster W, Mavromara P, Labropoulou V, Mitrani-Rosenbaum S. et al. 1993. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and movement of ancient human populations. J Virol 67:6413-6424.
22. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. 1998. Natural history of cervicovaginal papillomaiarus infection in young women. N Engl J Med 338:423-428.
23. Kammer C, Tommasino M, Syrjanen S, Delius H, Hebling U, Warthorst U, Poster H, Zehbe I. 2002. Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: Implications for cervical disease. Br J Cancer 86:269-273.
24. Lichtig H, Algrisi M, Edri-Botzer L, Abadi T, Verbitzky Y, Jackman A, Tommasino M, Zehbe I, Sherman L. 2006. HPV16 E6 natural variants exhibit different activities in functional assays relevant to the carcinogenic potential of E6. Virology 350:216-227.
25. Londesborough P, Ho L, Terry G, Cuzick J, Wheeler C, Singer A. 1996. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer 69:364-368.
26. Mantovani F, Massimi P, Banks L. 2001. Proteasome-mediated regulation of the hDlg tumour suppressor protein. J Cell Sci 114:4285-4292.
27. Miller D, Rosman GJ. 1989. Improved retroviral vectors for gene transfer and expression. Bio Tech 7:980-988.
28. Nindl I, Rindfleisch K, Kotz B, Schneider A, Durst M. 1999. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intraepithelial neoplsia and cervical cancer. Int J Cancer 82:203-207.
29. Nomine Y, Masson M, Charbonnier S, Zanier K, Ristriani T, Derychere F, Sibler A-P, Desplancq D, Atkinson RA, Weiss E, Orfanoudakis G, Kieffer B, Trave G. 2006. Structural and functional analysis of E6 oncoprotein: Insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell 21:665-678.
30. Pear WS, Nolan GP, Scott ML, Baltimore D. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 990:8392-8396.
31. Scheffner M, Whitaker NJ. 2003. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 13:59-67.
32. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus type 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
33. Scheurer ME, Tortolero-Luna G, Adler-Storthz K. 2005. Human papillomavirus infections: Biology, epidemiology, and prevention. Int J Gynecol Cancer 15:727-746.
34. Schlegel R, Phelps WC, Zhang Y-L, Barbosa M. 1988. Quantitative keratinocyte assay detects two biological activities of human papillomavirus and identifies viral types associated with cervical carcinoma. EMBO J 7:3181-3187.
35. Sedman SA, Hubbert NL, Vass WC, Lowy DR, Schiller JC. 1992. Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated transactivation or transforming activity. J Virol 66:4201-4208.
36. Sherman L, Schlegel R. 1996. Serum- and calcium-induced differentiation of human keratinocytes is inhibited by HPV16 E6 oncoprotein. J Virol 70:3269-3279.
37. Shnitman-Magal S, Jackman A, Pei X-F, Schlegel R, Sherman L. 1998. Induction of apoptosis in human keratinocytes containing mutated p53 alleles and its inhibition by both the E6 and E7 oncoproteins. Int J Cancer 75:96-104.
38. Shnitman Magal S, Jackman A, Ish-Shalom S, Edri Botzer L, Gonen P, Schlegel R, Sherman L. 2005. Downregulation of Bax mRNA expression and protein stability by the E6 protein of human papillomavirus 16. J Gen Virol 86:611-621.
39. Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, Villa LL. 2007. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 120:1763-1768.
40. Thomas M, Pim D, Banks L. 1999. The role of the E6 p53 interaction in the molecular pathogenesis of HPV. Oncogene 18:7690-7700.
41. Tornesello ML, Duraturo ML, Salatiello I, Buonaguro L, Losito S, Botti G, Stellato G, Greggi S, Piccoli R, Pilotti S, Stefanon B, De Palo G, Franceschi S, Buonaguro FM. 2004. Analysis of human papillomavirus Type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J Med Virol 74:117-126.
42. van Duin M, Snijders PJ, Vossen MT, Klaassen E, Voorhorst F, Verheijen RH, Heimerhorst TJ, Meijer CJ, Walboomer JM. 2000. Analysis of human papillomavirus type 16 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J Gen Virol 81:317-325.
43. Villa LL, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, Franco EL. 2000. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 81:2959-2968.
44. Xi LF, Demers GW, Koutsky LA, Kiviat NB, Kuypers J, Watts DH, Holmes KK, Galloway DA. 1995. Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J Infect Dis 172:747-755.
45. Xi LF, Koutsky LA, Galloway DA, Kuypers J, Hughes JP, Wheeler CM, Holmes KK, Kiviat NB. 1997. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst 89:796-802.
46. Xi L, Carter JJ, Galloway DA, Kuypers J, Hughes JP, Lee SK, Adam DE, Kiviat NB, Koutsky LA. 2002. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev 11:343-351.
47. Yamada T, Wheeler CM, Halpern AL, Stewart ACM, Hildesheim A, Jenison SA. 1995. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol 69:7743-7753.
48. Yamada T, Manos M, Peto J, Greer CE, Munoz N, Bosch FX, Wheeler CM. 1997. Human papillomavirus type 16 sequence variation in cervical cancers: A worldwide perspective. J Virol 71:2463-2472.
49. Zehbe I, Voglino G, Delius H, Wilander E, Tommasino M. 1998a. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet 352:1441-1442.
50. Zehbe I, Wilander E, Delius H, Tommasino M. 1998b. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res 58:829-833.
51. Zehbe I, Tachezy R, Mytilineos J, Voglino G, Mikyskova I, Delius H, Marongiu A, Gissmann L, Wilander E, Tommasino M. 2001. Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes. Int J Cancer 94:711-716.
52. Zehbe I, Mytilineos J, Wikstrom I, Henriksen R, Edler L, Tommasino M. 2003. Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol 64:538-542.
53. Zur-Hausen H. 1996. Papilloma virus infection - a major cause of human cancers. Biochim Biophys Acta 1288:F55-F78.